
SPIRIT-Outcomes 2022 Extension: guidelines for transparent inclusion of clinical trial outcomes in trial protocols
How to improve outcome reporting in clinical trial protocols: read more about the SPIRIT-Outcomes 2022 Extension.
A central online news resource for professionals involved in the development of medical publications and involved in publication planning and medical writing.
How to improve outcome reporting in clinical trial protocols: read more about the SPIRIT-Outcomes 2022 Extension.
The 17 items to include when reporting clinical trial outcomes. Read about the CONSORT-Outcomes 2022 Extension checklist for outcomes of all randomised clinical trials.
Read about new guidance from the PMCPA that aims to ensure the social media activities of pharmaceutical companies stay within the law.
Find out what’s new in the latest 2022 update to the ICMJE recommendations.
Find out what’s covered in the 2022 update to the Good Publication Practice guidelines.
Read about the new 28-item checklist developed to aid decision-making in health economic evaluations.
Read about recent roundtable recommendations for improving the transparency of real world evidence dissemination.
Recommendations from the ISMPP Authorship Task Force aim to clarify ICMJE guidelines on authorship selection criteria.
Dr Tony Ross-Hellauer (ON-MERRITT) discusses how the move toward open research may exacerbate inequity and suggests strategies to prevent it.
Read about Cochrane reviewers’ approaches to detecting and tackling potential fraud in clinical trial publications.
Missed the meeting? Read our report to get up to speed!
Missed the meeting? Read our report to get up to speed!
World Health Organization provides 6 principles for regulation and governance of the technology.
European countries can’t agree on what counts as research misconduct, creating potential pitfalls for researchers.
Missed the meeting? Read our report to get up to speed!
The ICMJE recently updated its recommendations, providing guidance on issues such as use of preprint servers, conflict of interest reporting and journal metrics.